{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:55:13Z","timestamp":1790726113138,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The contribution of lifestyle factors compared with HIV infection and antiretroviral therapy (ART)-related determinants to Metabolic Syndrome (MetS) in Women with HIV (WWH) remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the prevalence and determinants of MetS in the era of Integrase Strand Transfer Inhibitors (INSTI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Monocentric retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 297 WWH to assess the prevalence of MetS and its association with HIV-related and lifestyle factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MetS was diagnosed in 80 women (26%). Those with MetS showed lower CD4 nadir, longer HIV and ART duration, and greater exposure to protease inhibitors and INSTI, but none were independently associated with MetS or its components. Notably, lifestyle-related factors showed relatively strong associations with the study outcomes: physical activity was protective (OR 0.10, 95% CI 0.02\u20130.44), whereas physically demanding work increased risk (OR 6.58, 95% CI 2.03\u201326.26).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Lifestyle-related factors appeared to show stronger associations with MetS risk compared to HIV-related variables, underscoring the importance of systematic lifestyle assessment and targeted interventions in women with HIV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12981-026-00913-1","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:08:23Z","timestamp":1782907703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond HIV: investigating key drivers of metabolic syndrome in midlife women with HIV in the INSTI era"],"prefix":"10.1186","volume":"23","author":[{"given":"M.","family":"Poliseno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Brindicci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Capruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cianciaruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colavito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Giliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Lobalsamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Metrangolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Milano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Perrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. R.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"913_CR1","doi-asserted-by":"crossref","unstructured":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143\u2013421.","DOI":"10.1161\/circ.106.25.3143"},{"key":"913_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/jdi.12075","volume":"4","author":"JA Shin","year":"2013","unstructured":"Shin JA, Lee JH, Lim SY, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 2013;4:334\u201343.","journal-title":"J Diabetes Investig"},{"key":"913_CR3","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1161\/CIRCULATIONAHA.105.539528","volume":"112","author":"PW Wilson","year":"2005","unstructured":"Wilson PW, D\u2019Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112:3066\u201372.","journal-title":"Circulation"},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.2337\/dc07-0460","volume":"30","author":"LH Curtis","year":"2007","unstructured":"Curtis LH, Hammill BG, Bethel MA, et al. Costs of the metabolic syndrome in elderly individuals: findings from the Cardiovascular Health Study. Diabetes Care. 2007;30:2553\u20138.","journal-title":"Diabetes Care"},{"issue":"1","key":"913_CR5","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1186\/s12889-024-20118-3","volume":"24","author":"D Trachunthong","year":"2024","unstructured":"Trachunthong D, Tipayamongkholgul M, Chumseng S, et al. Burden of metabolic syndrome in the global adult HIV-infected population: a systematic review and meta-analysis. BMC Public Health. 2024;24(1):2657. https:\/\/doi.org\/10.1186\/s12889-024-20118-3.","journal-title":"BMC Public Health"},{"key":"913_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40265-016-0546-7","volume":"76","author":"DC Hsu","year":"2016","unstructured":"Hsu DC, Sereti I. Serious non-AIDS events: therapeutic targets of immune activation and chronic inflammation in HIV infection. Drugs. 2016;76:533\u201349.","journal-title":"Drugs"},{"key":"913_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/01.mjt.0000162013.66614.16","volume":"13","author":"G Barbaro","year":"2006","unstructured":"Barbaro G. Highly active antiretroviral therapy\u2013associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther. 2006;13:248\u201360.","journal-title":"Am J Ther"},{"key":"913_CR8","unstructured":"World Health Organization (WHO). Noncommunicable diseases. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/noncommunicable-diseases. Accessed on 14 Sep 2025."},{"key":"913_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13104-016-1953-2","volume":"9","author":"AT Hirigo","year":"2016","unstructured":"Hirigo AT, Tesfaye DY. Influences of gender in metabolic syndrome and its components among people living with HIV using antiretroviral treatment in Hawassa, southern Ethiopia. BMC Res Notes. 2016;9:145. https:\/\/doi.org\/10.1186\/s13104-016-1953-2.","journal-title":"BMC Res Notes"},{"key":"913_CR10","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/QAI.0b013e31817af461","volume":"48","author":"ME Sobieszczyk","year":"2008","unstructured":"Sobieszczyk ME, Hoover DR, Anastos K, et al. Prevalence and predictors of metabolic syndrome among HIV-infected and HIV-uninfected women in the Women\u2019s Interagency HIV Study. J Acquir Immune Defic Syndr. 2008;48:272\u201380.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"913_CR11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004987","volume":"6","author":"JV Baker","year":"2017","unstructured":"Baker JV, Sharma S, Achhra AC, et al. Changes in cardiovascular disease risk factors with immediate versus deferred antiretroviral therapy initiation among hiv\u2010positive participants in the START (Strategic Timing of Antiretroviral Treatment) trial. J Am Heart Assoc. 2017;6(5):e004987. https:\/\/doi.org\/10.1161\/JAHA.116.004987.","journal-title":"J Am Heart Assoc"},{"key":"913_CR12","unstructured":"The jamovi project (2025).jamovi(Version 2.6) [Computer Software]. https:\/\/www.jamovi.org"},{"issue":"6","key":"913_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/QAD.0000000000002811","volume":"35","author":"The RESPOND Study Group","year":"2021","unstructured":"The RESPOND Study Group. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents. AIDS. 2021;35(6):869\u201382. https:\/\/doi.org\/10.1097\/QAD.0000000000002811.","journal-title":"AIDS"},{"key":"913_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1089\/apc.2010.0360","volume":"25","author":"PR Alencastro","year":"2011","unstructured":"Alencastro PR, Fuchs SC, Wolff FH, et al. Independent predictors of metabolic syndrome in HIV-infected patients. AIDS Patient Care STDS. 2011;25:627\u201334.","journal-title":"AIDS Patient Care STDS"},{"issue":"3","key":"913_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bjid.2017.02.003","volume":"21","author":"LD Akl","year":"2017","unstructured":"Akl LD, Valadares ALR, Moraes MJ, et al. Metabolic syndrome in HIV-infected middle-aged women on antiretroviral therapy: prevalence and associated factors. Braz J Infect Dis. 2017;21(3):263\u20139. https:\/\/doi.org\/10.1016\/j.bjid.2017.02.003.","journal-title":"Braz J Infect Dis"},{"key":"913_CR16","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1089\/aid.2012.0048","volume":"28","author":"A Biron","year":"2012","unstructured":"Biron A, Bobin-Dubigeon C, Volteau C, et al. Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28:1672\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"913_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiag271","author":"K Bourgi","year":"2026","unstructured":"Bourgi K, Bian A, Boyd L, et al. Weight gain on contemporary integrase strand transfer inhibitors and tenofovir alafenamide in persons with HIV starting antiretroviral therapy in the United States and Canada. J Infect Dis. 2026. https:\/\/doi.org\/10.1093\/infdis\/jiag271.","journal-title":"J Infect Dis"},{"issue":"5","key":"913_CR18","doi-asserted-by":"publisher","first-page":"e306","DOI":"10.1016\/S2352-3018(25)00354-6","volume":"13","author":"EM Kileel","year":"2026","unstructured":"Kileel EM, Malvestutto CD, Zanni MV, et al. Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE. Lancet HIV. 2026;13(5):e306\u201315. https:\/\/doi.org\/10.1016\/S2352-3018(25)00354-6.","journal-title":"Lancet HIV"},{"issue":"6","key":"913_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252320","volume":"16","author":"LW Ang","year":"2021","unstructured":"Ang LW, Ng OT, Boudville IC, et al. An observational study of the prevalence of metabolic syndrome in treatment-experienced people living with HIV in Singapore. PLoS ONE. 2021;16(6):e0252320. https:\/\/doi.org\/10.1371\/journal.pone.0252320.","journal-title":"PLoS ONE"},{"issue":"22","key":"913_CR20","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa062360","volume":"355","author":"Strategies for Management of Antiretroviral Therapy (SMART) Study Group","year":"2006","unstructured":"Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283\u201396. https:\/\/doi.org\/10.1056\/NEJMoa062360.","journal-title":"N Engl J Med"},{"key":"913_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/15284336.2017.1311502","volume":"18","author":"L Calza","year":"2017","unstructured":"Calza L, Colangeli V, Magistrelli E, et al. Prevalence of metabolic syndrome in HIV-infected patients na\u00efve to antiretroviral therapy or receiving a first-line treatment. HIV Clin Trials. 2017;18:110\u20137.","journal-title":"HIV Clin Trials"},{"issue":"2","key":"913_CR22","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1097\/QAI.0000000000003719","volume":"100","author":"M Ranzenigo","year":"2025","unstructured":"Ranzenigo M, Diotallevi S, Lolatto R, et al. Prevalence and incidence of metabolic syndrome in people with HIV receiving cabotegravir and rilpivirine. J Acquir Immune Defic Syndr. 2025;100(2):e2\u20133. https:\/\/doi.org\/10.1097\/QAI.0000000000003719.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"913_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/nu11071652","volume":"11","author":"J Myers","year":"2019","unstructured":"Myers J, Kokkinos P, Nyelin E. Physical activity, cardiorespiratory fitness, and the metabolic syndrome. Nutrients. 2019;11(7):1652. https:\/\/doi.org\/10.3390\/nu11071652.","journal-title":"Nutrients"},{"key":"913_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-12074-z","volume":"21","author":"X Ying","year":"2021","unstructured":"Ying X, Yang S, Li S, et al. Prevalences of metabolic syndrome and its sex-specific association with socioeconomic status in rural China: a cross-sectional study. BMC Public Health. 2021;21:1\u20138.","journal-title":"BMC Public Health"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-026-00913-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00913-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-026-00913-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:56:26Z","timestamp":1790722586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12981-026-00913-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1186\/s12981-026-00913-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7766291\/v1","asserted-by":"object"}]},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Local Ethics Committee on June 16, 2025 (Prot. 2241\/CEI). All patients provided written informed consent for the use of anonymized data for research purposes.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent for the use of anonymized data for research purposes.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"92"}}